Taro Kishi   Yuki Matsuda   Shinji Matsunaga   Masatsugu Moriwaki   Yoichiro Otake   Kaku Akamatsu   Tomo Okochi   Shigeki Hirano   Toshihiko Funahashi   Momoko Okuda   Hideaki Tabuse   Kiyoshi Fujita   Nakao Iwata   
Neuropsychiatric Disease and Treatment 13 117-125 2017年1月 [査読有り]
Objective: There are no direct comparisons between escitalopram and paroxetine controlled release in patients with major depressive disorder (MDD). Methods: We conducted a 24-week, rater-masked, randomized trial of escitalopram (5–20 mg/day) versu...